Herbert Kellner

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial

Dominique Baeten, Xenofon Baraliakos, Jürgen Braun et al. · The Lancet · 2013 · 590 citations

Medicine, Clinical Sciences, Immunology +14

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study

Mark C. Genovese, Patrick Durez, Hanno B. Richards et al. · Annals of the Rheumatic Diseases · 2012 · 288 citations

Life Sciences, Immunology, Pharmacotherapy +17

Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study

Rieke Alten, Juan J. Gómez‐Reino, Patrick Durez et al. · BMC Musculoskeletal Disorders · 2011 · 151 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Targeting interleukin-17 in patients with active rheumatoid arthritis: rationale and clinical potential

Herbert Kellner · Therapeutic Advances in Musculoskeletal Disease · 2013 · 109 citations · Full text

Life Sciences, Immunology, Pathobiology +17

Association of Anti‐Cyclic Citrullinated Peptide Antibodies, Anti‐Citrullin Antibodies, and IgM and IgA Rheumatoid Factors with Serological Parameters of Disease Activity in Rheumatoid Arthritis

Alexander Greiner, Herbert Plischke, Herbert Kellner et al. · Annals of the New York Academy of Sciences · 2005 · 100 citations

Life Sciences, Immunology, Internal Medicine +17